

An Assessment of Faecal Occult Blood Test and *H. pylori* infection in Patients with Uninvestigated Dyspepsia in Primary Health Cares in Abakaliki, Nigeria

E Ugwuja, N Ugwu

Citation

E Ugwuja, N Ugwu. *An Assessment of Faecal Occult Blood Test and H. pylori infection in Patients with Uninvestigated Dyspepsia in Primary Health Cares in Abakaliki, Nigeria*. The Internet Journal of Laboratory Medicine. 2007 Volume 3 Number 1.

Abstract

Test for faecal occult blood (FOB) is commonly used to evaluate patients with intestinal disorders. An assessment of FOBT and infection with *H. pylori* using standard techniques was conducted among dyspeptic patients attending primary health cares in Abakaliki, Nigeria. Of the 262 patients screened, 163(62%) were FOB+ of which 64 [39.3% ((95% CI: 29.2-48.8%) were *H. pylori* seropositive. FOB+ patients were more likely than were FOB- patients to be seropositive for *H. pylori* (39.3% vs. 5.1%, OR = 12.2). Although no relationship was found between FOBT result and presence of intestinal parasites ($X^2 = 9.4$, $p > 0.05$), yeast cells were found more in stool samples of FOB+ than in FOB- dyspeptic patients [68 vs. 30 (95% CI: 0.051-0.329)]. FOBT remains a vital tool for assessing intestinal disorders and may be used for the initial evaluation and early management decisions when patients first present at the first visit to their GPs.

INTRODUCTION

Dyspepsia or more accurately, uninvestigated dyspepsia, a symptom complex arising in the upper gastrointestinal tract [1] has been described as a common complaint among individuals seeking medical care as well as people in the general population [2]. The symptom complex includes: upper abdominal/epigastric pain or discomfort, post-prandial fullness, bloating, belching, early satiety, anorexia, nausea, retching, vomiting, heartburn and regurgitation [2]. In absence of any underlying pathologies, such as peptic ulcer, gastroesophageal reflux, pancreatitis, biliary tract disease or others, dyspepsia is defined as functional or idiopathic dyspepsia. Data on dyspepsia prevalence, nearly all arising from studies in few developed geographical areas and countries, are of the order of 1-4% of all consultations in all primary care medicine [3]. However, estimates of adults affected by dyspepsia are as high as 20-40% [3, 4]. Variation in prevalence rates of dyspepsia has been partially related to difference in defining dyspepsia in the study population [5]. Although studies have shown that dyspepsia is associated with some physiological abnormalities [6,7,8,9], *Helicobacter pylori* (Hp) has been recognised as a key factor in the aetiology of various gastrointestinal diseases, ranging from chronic active gastritis without clinical symptoms to peptic

ulceration, gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue lymphoma [10,11]. The diagnosis of dyspepsia has been found to be challenging because patients often exhibit changing symptoms, and because characterisation of symptoms provide little information about the nature of the underlying physiologic abnormality [12]. In addition to history taking and standardised diagnostic techniques such as endoscopies, histological examination (H), rapid urease test (RUT) and ¹³C-urea breath test (UBT) to diagnose *H. pylori* [13], faecal occult blood test (FOBT) is also used in the screening and monitoring of patients with gastrointestinal disorders [14, 15]. For instance, annual or biennial faecal occult screening has been shown to significantly reduce the incidence of colorectal cancer [16, 17]. Although upper gastrointestinal endoscopy is a valuable diagnostic tool, its role is controversial in patients with dyspepsia [18,19,20]. This study was aimed at providing baseline data on routine faecal occult blood testing and prevalence of *H. pylori* infection among dyspeptic patients attending primary health cares. The public health implications of the findings with reference to the general well being of dyspeptic patients are discussed.

MATERIALS AND METHODS

The study area is defined by longitude 8 ° E and latitude 6 °

N, elevated at 380ft above sea level. The vegetation characteristic is that of the tropical rain forest with an average annual rainfall of about 1,600mm and an average atmospheric temperature of 30 ° C. There are two distinct seasons, the wet and the dry seasons; the former takes place between April and October, while the latter occurs from November to March. The main occupation of the people is subsistence farming (mainly yam and cassava) with some animal husbandry and other professions and/ or activities such as civil service, trading, artisans, and stone quarrying.

This study was conducted at the Department of Chemical Pathology, Ebonyi State University, Abakaliki. The proposal for this study was approved by the Research and Ethics Committee of Ebonyi State University Teaching Hospital, Abakaliki. Participants were consecutive referrals from general practitioners (GPs) in Abakaliki metropolis who came for laboratory investigations as part of evaluation for various dyspeptic complaints. The clinical presentation, diagnosis, drug treatment and duration of symptoms were noted. Before enrolment, informed consent of the participants were sought and obtained. Patients that satisfied the conditions of not being on proton pump inhibitors, H₂ receptor blocker and non-steroid anti-inflammatory drugs (NSAIDs) for the past one month (4wks) were enrolled. Excluded from the study were patients with any known clinical conditions that may interfere with the result of this study, refusal to give consent or patients that have been on treatment with non-steroid anti-inflammatory drugs (NSAIDs) four weeks prior to enrolment. In all, a total of two hundred and sixty two (262) patients (117 males and 145 females) aged 5.5 to 56 years were found to be eligible for the study. At entry into the study each participant was interviewed to obtain sociodemographic data such as age, sex, level of education and occupation. Stool samples were collected into chemically clean wide mouthed plastic containers for faecal occult blood test and routine stool microscopy. Venous blood were obtained into dry glass test tubes for clotting and retraction to take place, after which samples were centrifugation at 2000g for two minutes and the serum separated for the determination of specific immunoglobulin G (IgG) to *Helicobacter pylori*.

Faecal occult blood test was done by rapid one-step immunoassay technique for qualitative determination of human haemoglobin in faeces (Occult Blood Brand, CAL-TECH Diagnostics, INC. Chino, California, USA), while routine stool microscopy was done by both direct wet mount

and formol concentration techniques for identification of intestinal parasites [21]. *Helicobacter pylori* detection was done by an enzyme-linked immunosorbent assay for the identification of immunoglobulin G [22]. All samples were analysed fresh.

STATISTICAL ANALYSIS

Data were analysed for mean, proportion (expressed as percentage), and odd ratio. 95% confidence intervals were calculated where appropriate. Test for statistical significance was done by Chi square at 95% level of significance ($p < 0.05$).

RESULTS

In the 262 patients studied, presenting symptoms include, heartburn [$n= 45$ (17%)], abdominal pain [$n= 68$ (26%)], bloating [$n= 91$ (35%)], vomiting [$n= 58$ (22%)]. The duration of symptoms ranged 6 months to 2 years (mean = 1.1 years).

Figure 1

Table 1: Age and sex distribution of dyspeptic patients (percentage in parenthesis)

Age groups (years)	Males	Females	Total
≤ 20	17 (36.2)	30 (68.2)	47
21-30	20 (25.6)	58 (74.4)	78
31-40	31 (40.8)	45 (59.2)	76
41-50	44 (81.5)	10 (18.5)	54
> 50	5 (71.4)	2 (28.6)	7
Total	117 (44.7)	145 (55.3)	262

Table 1 shows the age and sex distribution of patients. The patients' ages ranged from 5.5 to 56 years (mean = 38.6 ± 5.2 years) and most were from low socioeconomic background (data not shown). Although females formed greater proportion of the patients, there was no significant sex difference ($p > 0.05$). Majority of the patients presenting with dyspepsia were in the age range 50 years and below.

Figure 2

Table 2: Age and sex distribution of FOB and HP dyspeptic patients (percentage in parenthesis).

Age group (years)	FOB*			HP*			FOB*: HP*
	Male	Female	Total	Male	Female	Total	
≤ 20	8 (50)	8 (50)	16	2 (40)	3 (60)	5	3.2: 1
21-30	7 (14.9)	40 (85.1)	47	1 (5.3)	18 (94.7)	19	2.5: 1
31-40	27 (47.4)	30 (52.6)	57	14 (60.9)	9 (39.1)	23	2.5: 1
41-50	32 (84.2)	6 (15.8)	38	15 (93.8)	1 (6.2)	16	2.4: 1
> 50	3 (60)	2 (40)	5	1 (100)	0 (0)	1	5.0: 1
Total	77 (47.2)	86 (52.8)	163	33 (47.8)	31 (52.2)	64	3.1 : 1

Legend

FOB* Faecal occult blood positive
HP* Helicobacter pylori positive

A total of 163 (62.2%) patients were positive for faecal occult blood test of which 77 (47.2%) were males and 86 (52.2%) were females, although there was no statistically significant difference (95% CI: -0.184-0.064) between the sexes (table 2). Similarly, there was no significant difference in *H. pylori* infection between the males and the females [47.8% vs. 52.2%, (95% CI: - 0.184-0.064)], however, majority of the patients positive for both faecal occult blood test and *H. pylori* test were in the age range 21-50 years (table 2).

Figure 3

Table 3: positivity among FOB and FOB dyspeptic patients

	HP*	HP ⁻	Total
FOB*	64	99	163
FOB ⁻	5	94	99
Total	69	193	262

Legend

FOB* Faecal occult blood positive
HP* Helicobacter pylori positive
 $\chi^2 = 26.9, p < 0.05$
Odd ratio $64 \times 94 / 99 \times 5 = 6016/495 = 12.2$

From table 3, the prevalence of *H. pylori* infection among dyspeptic patients with positive and negative faecal occult blood test was 39.3% (95% CI: 29.2-48.8%) and 5.1% (95%CI: 0.6 – 9.4%) respectively. Dyspeptic patients with positive faecal occult blood test were more likely than were patients with negative results to be anti-*H. pylori* IgG

positive (39.3% vs. 5.1%, Odd ratio = 12.2). *Entamoeba histolytica* was the major pathogen identified in stool samples of patients (table 4).

Figure 4

Table 4: Comparison of pathogens found in FOB and FOB dyspeptic patients.

Organism	FOB +	FOB -	Total
<i>Entamoeba histolytica</i>	28	27	55
<i>Gardia lamblia</i>	2	2	4
<i>Ancylostoma duodenales</i>	3	2	5
<i>Ascaris lumbricoides</i>	0	1	1
<i>Candida albicans</i> *	68	30	98
Total	101	62	163

* Significantly different.

Legend

FOB+ Faecal occult blood positive
HP+ Helicobacter pylori positive

Others are *Gardia lamblia*, *Ancylostoma duodenales* (hook worm), *Ascaris lumbricoides* (round worm) and *Candida albicans* (yeast cells). The results of faecal occult blood test were not dependent on the presence of parasites in the stool as there was no significant difference in the rate of infection between the FOB + and FOB - patients ($X^2 = 9.4, p > 0.05$), however, yeast cells were found more in stool samples of FOB + than in FOB - patients [68 vs. 30 (95% CI: 0.051-0.329)].

DISCUSSION

Considerable interest exists in the use of non-invasive testing in place of endoscopy in determining the management protocol for patients presenting with upper gastrointestinal symptoms [23]. The use of faecal occult blood test is common among general practitioners in the primary health cares; however, its role in evaluating patients with dyspepsia has not been documented. In the present study, dyspeptic patients with positive faecal occult blood test were more likely than were patients with negative results to be anti-*H. pylori* IgG positive (39.3% vs. 5.1%, Odd ratio = 12.2). To the best of our knowledge, this report is the first to document an association between *H. pylori* seropositivity and faecal occult blood test result, and needs to be confirmed in another setting involving larger number of participants. Although no specific investigation was done to assess the integrity of gastric mucosa of our patients, as that was not part of the original design, more gastrointestinal bleeding in *H. pylori* infected patients than non-infected patients cannot be ruled out. For instance, the prevalence of peptic ulcer has been found to be higher in dyspeptic patients with *H. pylori* infection than in patients without infection [24]. *H. pylori*

may induce internal bleeding by production of cytotoxins which weaken gastric mucosa barrier and permits back diffusion of hydrogen ions resulting in tissue damage [25]. Also, *H. pylori* infection has been associated with reversible lowering of gastric juice ascorbate and may predispose to gastric cancer and peptic ulcerations [26]. The role of *H. pylori* in GI bleeding has equally been demonstrated in *H. pylori* eradication study [27] where *H. pylori* eradication was found to eliminate further gastrointestinal bleeding in patients who have had bleeding episode with established ulcers. Although specifically for the detection of gastrointestinal (GI) bleeding, faecal occult blood testing may have some implications for dyspeptic patients. For example, despite some side effects such as disruption of lifestyle and anxiety caused by falsely positive screening tests, some benefits have however been associated with faecal occult blood screening [14, 16]. Faecal occult blood screening has been associated with reduction in colorectal cancer, possible reduction in cancer incidence through early detection and removal of colorectal adenomas [17]. However, studies have shown that many diseases such as colon cancer, polyps, colitis diverticulitis and other gastrointestinal problem can cause occult blood in stool [28]. In primary health settings, early detection of internal bleeding through faecal occult blood testing might have important implications for early management decisions when patients first present with dyspepsia. It has been shown that *H. pylori* infection is a useful predictor of endoscopic diagnosis in patients with dyspepsia and in patients without *H. pylori* infection, ulcer disease is extremely rare and endoscopic examination is usually normal or shows evidence of oesophagitis [29]. In dyspeptic patients with *H. pylori* infection, endoscopy shows underlying ulcer disease in 10-50% [30, 31]. Endoscopic finding reported an overall prevalence of peptic ulcer to be 8.5% in adult population and 21% in *H. pylori* seropositive patients [24]. In the present study, the seroprevalence of *H. pylori* infection in FOB⁺ patients was 39.3%, a lower value than 55% reported by Vaira et al. [24] but higher than that reported by Sobala et al. [32]. This variation in prevalence of *H. pylori* in patients with dyspepsia may be attributed partly to differences in socioeconomic status [33]. However, in the present study, not all dyspeptic patients have *H. pylori* infection, suggesting the involvement of other factors in the aetiology of dyspepsia in this population. For instance, symptoms of dyspepsia have been found in individuals with gastric dysmotility, modified gastric output or altered visceral

sensibility, psychological problems, gastroesophageal reflux and irritable bowel [11, 34, 35]. The comparable rate of infection with *H. pylori* and symptoms of dyspepsia between males and females in the present study corroborates earlier study [2]. Similarly, the presence of more FOB⁺ and HP⁺ in older patients corroborates the report of Veldhuyzen van Zanten [36] and affirms the age dependent increase in *H. pylori* infection, a phenomenon that has been attributed to continuous risk of infection [37]. This study also found no significant difference in the rate of infection with intestinal parasites between dyspeptic patients with or without positive faecal occult blood test and/or *Helicobacter pylori* serology. However, it is interesting to note that although yeast cells are considered normal intestinal flora, its presence in more stool samples from dyspeptic patients with positive faecal occult blood test than samples from patients with negative results (68 vs.30) warrants further studies as the role of yeast cell in the pathogenesis of dyspepsia cannot be ruled out. Infestation with *Entamoeba histolytica* was also prominent in our patients. Amoebiasis can disrupt the protective mucus layer overlying the colonic mucosa [38]. The resulting epithelial ulcerations can bleed and cause colitis, usually 2-6 weeks after initial infection [38, 39]. Similarly infection with *Gardia lamblia*, which is stimulated by bile, carbohydrates, and low oxygen tension, can cause dyspepsia, malabsorption, and diarrhoea. A recent theory suggests that the symptoms are the result of brush border enzyme deficiency rather than invasion of the intestinal wall [40]. In conclusion, faecal occult blood test remains an accepted and well-established component of screening patients with intestinal disorders and may be used for the initial evaluation and early management decisions when patients first present with dyspepsia at the first visit to their GPs. However, to avoid overestimation or underestimation of positive faecal occult blood test result and the attendant health implications preliminary findings should be confirmed by other standardised investigations.

ACKNOWLEDGEMENT

The authors are grateful to the management and staff of Junico Biomedical Laboratories for their logistic support.

CORRESPONDENCE TO

Ugwuja, E. I. Department of Chemical Pathology, Faculty of Clinical Medicine, Ebonyi State University, P.M.B 053, Abakaliki, Nigeria. E-mail: ugwuja@yahoo.com Phone: +2347035122010.

References

1. Chiba N. Definition of dyspepsia: time for a reappraisal. *Eur. J. Surg. Suppl.* 1998; 583: 14-23.
2. Shaib Y and El-Serag HB. The prevalence and risk factors of functional dyspepsia in a multiethnic population in the United States. *Am. J. Gastroenterol.* 2004; 99 (11): 2210-2216.
3. Malfertheiner P. Current concepts in dyspepsia: a world perspective. *Eur. J. Gastroenterol. Hepatol.* 1999; Suppl 1: S25-9.
4. Westbrook JI, Talley NJ, McIntosh JH. et. al.. Prevalence of dyspepsia in NSW: A pilot survey. *J. Gastroenterol. Hepatol.* 1997; 12: A103.
5. Westbrook JI, McIntosh JH and Talley NJ. The impact of dyspepsia definition on prevalence estimates: Considerations for future researchers. *Scand. J. Gastroenterol.* 2000; 35 (3): 22733.
6. Troncon LE, Bennett RJ, Ahluwalia NK and Thompson DG. Abnormal intragastric distribution of food during gastric emptying in functional dyspepsia patients. *Gut* 1994; 35: 327-332.
7. Samsom M, Verhagen Ma, Van Berge Henegouwen GP and Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. *Gastroenterology* 1999; 116 (3): 761-2.
8. Tack J, Caenepeel P, Arts J, Lee KJ, Sifrim D and Janssens J. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. *Gut* 2005; 54:54 (10): 1370-6.
9. Kindt S and Tack J. Impaired gastric accommodation and its role in dyspepsia. *Gut* 2006; 55: 1685-1691.
10. Kusters JG, van Vliet AHM and Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. *Clin. Microbiol. Rev.* 2006; 19 (3): 449-490.
11. Carella AM, Bianco G, D'Alessandro V, Vilella M, D'Amico G, Mazzoccoli G, Sperandeo M, Annese MA and Sabella G. *Clin. Ter.* 1999; 150 (1): 67-76.
12. Malagelada JR. Functional dyspepsia. Insights on mechanisms and management strategies. *Gastroenterol. Clin. North Am.* 1996; 25: 103-12.
13. Dickerson LM and King DE. Evaluation and management of Nonulcer Dyspepsia. *Am. Fam. Physician* 2004; 70: 107-14.
14. Jorgensen OD, Kronborg O and Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. *Gut* 2002; 50 (1): 53-5.
15. Gisbert JP, Boixeda D, Martin De Argila C, Alvarez Baleriola I, Abaira V and Garcia Plaza A. Unhealed duodenal ulcers despite *Helicobacter pylori* eradication. *Scand. J. Gastroenterol.* 1997; 32 (7): 643-50.
16. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC and Schuma LM. The effect of faecal occult blood screening on the incidence of colorectal cancer. *N. Engl. J. med.* 2000; 343 (22): 1603-7.
17. Towler BP, Irwig L, Glassiou P, Weller D and Kewenter J. Screening for colorectal cancer using the faecal occult blood test, haemoccult. *Cochrane Database Syst. Rev.* 2000; ("): CD001216.
18. Fisher RS and Parkman HP. Management of nonulcer dyspepsia. *N. Engl. J. Med.* 1998; 339: 1376-81.
19. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et. al. European *Helicobacter pylori* Study Group (EHPSG). Current concepts in the management of *Helicobacter pylori* infection-the Maastricht 2-2000 consensus report. *Aliment. Pharmacol Ther.* 2002; 16: 167-80.
20. Liberman D and Hamilton F. NIH-ADHF Workshop on Endoscopy Priorities: workshop statement and recommendations. American Digestive Health Foundation. *Gastrointest. Endosc.* 1999; 49 (3 pt.2): S3-4.
21. Cheesbrough M. District laboratory practice in Tropical countries part 1. Cambridge University Press 1998; Pp 191-235.
22. Pronovost AD, Rose SL, Pawlak JW, Robin H and Schneider R. Evaluation of new immunodiagnostic assay for *Helicobacter pylori* antibody detection: correlation with histopathological and microbiological results. *Journal of Clinical Microbiology* 1994; 32: 46-50.
23. McColl KEL, Murray LS, Gillen D, Walker A, Wirz A, Fletcher J, Mowat C, Henry E, Kelman A and Dickson A. Randomised trial of endoscopy with testing for *Helicobacter pylori* compared with non-invasive *H. pylori* testing alone in the management of dyspepsia. *BMJ* 2002; 324:999.
24. Vaira D, Miglioli M, Mule P, Holton J, Menegatti M, Vergura M, Biasco G, Conte R, Logan RPH and Barbara L. Prevalence of peptic ulcer in *Helicobacter pylori* positive blood donors. *Gut.* 1994; 35: 309-12.
25. Crabtree JE, Taylor JD, Wyatt JI, Heatley RV, Shallcross TM, Tompkins DS and Rathbone BJ. Mucosal IgA recognition of *Helicobacter pylori* 120kDa protein, peptic ulceration and gastric pathology. *Lancet* 1991; 338:332-5.
26. Banerjee S, Hawksby C, Miller S, Dahill S, Beattie AD and McColl KEL. Effect of *Helicobacter pylori* and its eradication on gastric juice ascorbic acid. *Gut* 1994; 35: 317-22.
27. Graham DY, Hepps KS, Ramirez FC, Lew GM and Saeed ZA. Treatment of *Helicobacter pylori* reduces the rate of rebleeding in peptic ulcer disease. *Scand J Gastroenterol* 1993; 28: 939-42.
28. Simon JB. Occult blood screening for colorectal carcinoma: A critical review. *Gastroenterology* 1985; 88: 820.
29. Asante MA, Mendall M, Patel P, Ballam L and Northfield TC. A randomised trial of endoscopy vs. no endoscopy in the management of seronegative *Helicobacter pylori* dyspepsia. *Eur. J. gastroenterol Hepatol* 1998; 10: 983-9.
30. Patel P, Khulusi S, Mendall MA, Lloyd R, Jazrawi R, Maxwell JD and Northfield TC. Prospective screening of dyspeptic patients by *Helicobacter pylori* serology. *Lancet* 1995; 346 (8986): 1315-8.
31. Heaney A, Collins JSA, Watson EGP, McFarland RJ, Bamford KB and Tham TCK. A prospective randomised trial of a 'test and treat' policy versus endoscopy based management in young *Helicobacter pylori* positive patients with ulcer-like dyspepsia, referred to hospital clinic. *Gut.* 1999; 45: 186-90.
32. Sobala GM, Crabtree JE, Pentith JA, Rathbone BJ, Shallcross TM, Wyatt JI, Dixon MF, Heatley RV and Axon ATR. Screening dyspepsia by serology to *Helicobacter pylori*. *Lancet* 1991; 338: 94-6.
33. Ugwuja EI, Ugwu NC. *Helicobacter pylori* In Uninvestigated Dyspepsia in Primary Cares in Abakaliki, Nigeria. *Online J Health Allied Scs.* 2007;1:4
34. Thumshirn M, Camilleri M, Saslow SB. et. al.. Gastric accommodation in non-ulcer dyspepsia and the roles of *helicobacter pylori* infection and vagal function. *Gut.* 1999; 103: 768-74.
35. Soo S, Forman D, Delaney BC and Moayyedi P. A systemic review of psychological therapies for nonulcer dyspepsia. *Am. J. Gastroenterol.* 2004; 99 (9): 1817-22.
36. Veldhuyzen van Zanten SJO, Pollak PT, Best LM,

Bezanson GS and Marrie T. Increasing prevalence of *Helicobacter pylori* infection with age: continuous risk of infection in adults rather than cohort effect. *J. Infect. Dis.* 1994; 169: 434-7.

37. Mosiienko HP. Some features of functional gastroenterological diseases in young people. *Lik Sprava.* 2006; 4: 37-41.

38. Kucik CJ, Martin GL and Sortor BV. Common intestinal parasites. *Am. Fam Physician* 2004; 60: 1161-8.

39. Stanley SJ. Pathophysiology of amoebiasis. *Trends Parasitol.* 2001; 17: 280-5.

40. Leder K and Weller P. Gardiasis. In: Rose BD (Ed). *Infectious diseases.* Wellesley, Mass: up to date, 2002.

Author Information

Emmanuel Ike Ugwuja, M.Sc; MIBMS (UK)

Department of Chemical Pathology, Faculty of Clinical Medicine, Ebonyi State University

Nicholas Chukwuka Ugwu, M.Sc; MIBMS (UK)

Department of Chemical Pathology, Faculty of Clinical Medicine, Ebonyi State University